An 82-year-old male with a history of STEMI in 2013, stroke in 2018, cancer, and permanent AF, presented with acute heart failure with predominant right-side failure. Severe tricuspid regurgitation was identified.
The operators implanted an Evoque valve percutaneously under TEE guidance and general anaesthesia via the venous...

A 53-year-old male with a history of advanced malignancy (lung adenoma) and mid LAD PCI last year, along with multiple risk factors (hypertension, dyslipidemia, diabetes, and smoking), presented with angina and a positive stress test and CT. The angiography and CT showed significant left main stenosis...

A 77-year-old male with a history of SAVR in 2011 (Magna Ease 23) and moderate chronic kidney disease, with preservedLV function, presented with symptomatic severe aortic regurgitation and stenosis, associated with severe MR.

A Sapien 3 Ultra Resilia 23 valve was implanted under local anesthesia, with hemodynamic...

An 84-year-old woman with diabetes mellitus, frailty (5/6), preserved LV function, and aortic stenosis previously treated with CoreValve 26 mm in 2016, presented with symptomatic degenerative stenosis of the valve.
A Sapien 3 (23 mm) was implanted without predilatation but with post-dilatation under general anaesthesia, using cerebral...

Join us for a LIVE case followed by a recorded case highlighting advanced treatments for severe secondary mitral regurgitation:

• A 75-year-old man with permanent AF, a history of CABG, and symptomatic severe secondary MR (atrial and ischemic causes) with low LV function (45%) underwent mitral repair with...

Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.

At TCT Connect 2020, David J. Cohen (Kansas City, Missouri, USA) presented results from an analysis of the TVT registry focusing on impact of Cerebral Embolic Protection (CEP) on TAVR outcomes. Nicolas Dumonteil provides a summary of the key messages.

TCT 2021: Radoslaw Parma reviews the CHOICE-CLOSURE multicentre, randomized, controlled, open-label clinical trial presented by Mohamed Abdel-Wahab. The study compared outcomes of percutaneous femoral artery closure using a plug-based and a primary suture-based strategy in patients undergoing TAVI.

Mirvat Alasnag provides her take on the SENIOR-RITA trial, presented by Vijay Kunadian at the ESC Congress 2024 in London.

Alex Sticchi provides his take on the TRIGISTRY study presented by Julien Dreyfus at the ESC Congress 2024 in London.

Simultaneous publication in European Heart Journal, ehae578

Ali Nazmi Calik provides his take on UNIVERSAL randomized clinical trial, which questioned whether routine ultrasonography guidance for CFA access for cardiac procedures reduces bleeding or vascular complications. This trial was presented by Sanjit S. Jolly during TCT 2022.

Following the Hot Line session of the ESC Congress 2021 presented by George Dangas (New-York, USA), Daniele Giacoppo offers us a condensed version of this study.

Vijay Kunadian provides a summary of the coronary & structural late-breaking studies presented during TCT Connect 2020 and shares some take-home messages. See how these studies might influence your daily practice!

At TCT Connect 2020, Late-Breaking Trial Session II, the primary results of the Safety and Efficacy Comparison of Two TAVI Systems in a Prospective Randomized Evaluation (SCOPE) 2 trial were presented and simultaneously published in Circulation. Daniele Giacoppo provides a summary of the trial.

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.